Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Accounts Payables (2023 - 2025)

Onconetix (ONCO) has disclosed Accounts Payables for 2 consecutive years, with $4.1 million as the latest value for Q3 2024.

  • On a quarterly basis, Accounts Payables rose 356.93% to $4.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.1 million, a 356.93% increase, with the full-year FY2023 number at $1.8 million, changed N/A from a year prior.
  • Accounts Payables was $4.1 million for Q3 2024 at Onconetix, up from $1.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.3 million in Q1 2024 to a low of $900000.0 in Q3 2023.